

**Independent Auditor's Review Report on Standalone Quarterly Financial**  
**Results of the Company pursuant to the Regulation 33 of the SEBI (Listing**  
**Obligations and Disclosure Requirements ) Regulations,2015**

We have reviewed the accompanying statement of unaudited standalone financial results ("Statement") of **M/s Parabolic Drugs Limited ("the Company")** having **Registered Office at SCO 99-100, Top Floor, Sector-17B, Chandigarh** for the **Quarter/Half Year ended 30<sup>th</sup> September, 2017** being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements ) Regulations,2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the entity*, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above and **subject to Annexure-A**, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable Indian accounting standards (Ind AS) specified under section 133 of the Companies Act, 2013 and SEBI Circulars CIR/CFD/CMD/15/2015 dated 30 November 2015 and CIR/CFD/FAC/62/2016 dated 5 July 2016 , and other recognized accounting practices and policies has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Chandigarh;**

**Dated: 13<sup>th</sup> November, 2017**

**FOR V K JINDAL & ASSOCIATES.,**

**CHARTERED ACCOUNTANTS**

**FRN No.005244N**



**(Vijay Jindal)**

**Partner**

**Membership No: 084128**

**V.K. JINDAL & ASSOCIATES**  
**CHARTERED ACCOUNTANTS**

**PLOT NO. 5, SECTOR-1**  
**INDUSTRIAL AREA,**  
**PARWANOO.**  
**PH. 01792-233229.**  
**MOB. NO. 08699229555**

**Annexure A**

**Notes on the Un audited financial results of M/s Parabolic Drugs Limited**

**For the Quarter/Half Year ended 30<sup>th</sup> September, 2017**

1. Debit or Credit Balances on whatever account are subject to confirmation.
2. Depreciation has been provided for on pro-rata basis as per Companies Act, 2013.
3. Figures of the previous year/Quarter/Three months have been rearranged/regrouped wherever considered necessary.
4. Other operating income for the three months ended 30 September, 2017 includes Rs.0.27 crores which is subject to reconciliation and confirmation.

**Chandigarh;**

**Dated: 13<sup>th</sup> November, 2017**

**FOR V K JINDAL & ASSOCIATES**  
**CHARTERED ACCOUNTANTS**

**FRN No.00524418**

**(Vijay Jindal)**

**Partner**

**Membership No: 084128**



# PARABOLIC DRUGS LTD.

CIN No. : L24231CH1996PLC017755.

Parabolic Drugs Limited

Registered Office: SCO. 99 - 100, Top Floor, Sector - 17B, Chandigarh


Statement of Un-audited Financial Results for the Quarter/ Half year ended 30<sup>th</sup> Sept. 2017

Sr. No.	Particulars	Quarter ended			Half year ended	Corresponding half year ended	Previous year ended
		30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016	31.03.2017
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations						
	(a) Net Sales (Net of Excise duty)	23.96	15.33	14.14	39.29	24.98	69.12
	(b) Other Operating Income	(0.00)	0.70	0.59	0.70	0.79	4.60
	Total Revenue from Operations (Net of Excise Duty)	23.96	16.03	14.73	39.99	25.77	73.72
II	Other Income	0.34	3.78	1.69	4.12	1.79	4.25
III	Total Income (I + II)	24.30	19.81	16.42	44.11	27.56	77.97
IV	Expenses:						
	(a) Cost of materials consumed	21.53	14.02	10.20	35.55	22.14	64.08
	(b) Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods work-in-progress and Stock-in-Trade	(0.88)	(0.03)	(1.08)	(0.91)	25.17	27.86
	(d) Employees benefits expense	2.46	2.37	2.01	4.83	3.80	8.68
	(e) Finance Cost	1.80	2.56	28.32	4.36	60.21	9.91
	(f) Depreciation and amortization expense	8.65	8.65	13.39	17.30	26.77	53.49
	(g) Other expenses	4.52	4.41	5.20	8.92	8.46	19.19
	Total expenses (IV)	38.08	31.97	58.04	70.05	146.55	183.20
V	Profit / (Loss) before exceptional and extraordinary items and tax (III-IV)	(13.78)	(12.16)	(41.62)	(25.94)	(118.99)	(105.23)
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit / (Loss) before extraordinary items and tax (V - VI)	(13.78)	(12.16)	(41.62)	(25.94)	(118.99)	(105.23)
VIII	Tax expenses:						
	(a) Current tax	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Deferred tax	0.45	0.45	1.55	0.90	1.55	3.05
IX	Net Profit / (Loss) after tax from Continuing Operations (VII-VIII)	(14.23)	(12.61)	(43.17)	(26.84)	(120.53)	(108.28)
X	Other Comprehensive Income	0.00	0.00	0.05	0.00	0.10	0.21
XI	Total Comprehensive Income / (Expense) (Net of Tax)	(14.23)	(12.61)	(43.12)	(26.84)	(120.43)	(108.07)
XII	Paid-up Equity share capital (Face value of Rs.10/- each)						
	- Issued and Subscribed Capital	61.89	61.89	61.89	61.89	61.89	61.89
XIII	Earning Per Share (EPS) (Equity shares of Rs. 10/- each fully paid up)						
	a) Basic in Rs.	(2.30)	(2.04)	(6.97)	(4.34)	(19.46)	(17.46)
	b) Diluted in Rs.	(2.30)	(2.04)	(6.97)	(4.34)	(19.46)	(17.46)

## Notes :

- The above quarterly results have been reviewed & recommended by the Audit Committee and taken on record by the Board of Directors in their meeting held on 13th November 2017 and the same have been reviewed by the Statutory Auditors.
- During the period under review, the company has incurred loss owing to the unfavorable market conditions, interest burden and economic stress, the company has witnessed an erosion in the margins of key products.
- The promoters' shareholding (22619927 Equity shares) has been pledged pursuant to the terms of CDR package.
- The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.
- During the quarter ended 30<sup>th</sup> Sept, 2017, most of Banks have not charged interest due to NPA Status of Loan Accounts. Hence no Provision for interest for the quarter ended 30th Sept, 2017 on these loans has been made on the belief that such interest would be waived at the time of final settlement.
- As per Ind AS 18, Revenue for the quarter / half year ended September 30, 2017 is reported net of duties.

Place : Chandigarh  
Date : 13th Nov 2017



For Parabolic Drugs Limited

Pranav Gupta  
Managing Director

Regd. & Corp. Office : S.C.O. 99 - 100, Top Floor, Sector 17 - B,  
Chandigarh - 160 017 (India) Tel. : +91-172-3914646/3914647

Works - I : Village Sundhran, P.O. Mubarakpur, Dera Bas  
Distt. Mohali, Punjab, India Tel. : +91-1762 -308657  
website : www.parabolicdrugs.com





# PARABOLIC DRUGS LTD.

Parabolic Drugs Limited

CIN No. : L24231CH1996PLC017755

Statement of Assets and Liabilities as at 30th September 2017

Rs. In Crores

Sr.no.	Particulars	As at 30/09/2017	As at 31/03/2017
		Unaudited	Audited
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-Current Assets</b>		
	(a) Property, Plant and equipment	337.14	348.84
	(b) Capital Work in progress	6.52	6.52
	(c) Non current Investments	6.34	6.33
	(d) Other non-current assets	8.66	15.13
	<b>Total Non-Current Assets</b>	<b>358.66</b>	<b>376.82</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Inventories	15.57	15.25
	(b) Trade Receivables	83.51	66.96
	(c) Cash and cash equivalents	0.68	0.60
	(d) Short term loans and advances	29.04	29.61
	(e) Other Current assets	3.85	4.14
	<b>Total Current Assets</b>	<b>132.65</b>	<b>116.56</b>
	<b>TOTAL ASSETS</b>	<b>491.31</b>	<b>493.38</b>
<b>B</b>	<b>EQUITY &amp; LIABILITIES</b>		
<b>1</b>	<b>Equity</b>		
	(a) Equity Share Capital	61.89	61.89
	(b) Other Equity	(904.06)	(877.22)
	(c) Share application money pending for allot	26.00	26.00
	<b>Total Equity</b>	<b>(816.17)</b>	<b>(789.33)</b>
<b>2</b>	<b>Non-current liabilities</b>		
	(a) Financial Liabilities		
	- Borrowings	836.42	836.30
	(b) Provisions	1.19	1.22
	(c) Deferred Tax Liabilities (Net)	33.84	32.94
	<b>Total Non-current liabilities</b>	<b>871.45</b>	<b>870.46</b>
<b>3</b>	<b>Current Liabilities</b>		
	(a) Financial Liabilities		
	- Borrowings	145.41	143.17
	- Trade Payables	127.35	105.77
	(b) Other Current Liabilities	163.27	163.31
	<b>Total Current liabilities</b>	<b>436.03</b>	<b>412.25</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>491.31</b>	<b>493.38</b>

